Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study

Andersen, Mette Louise; Zegers, Floor Dijkstra; Jølving, Line Riis; Knudsen, Torben; Stenager, Egon; Nørgård, Bente Mertz

doi:10.1016/j.msard.2023.105031

Cited by 7 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher incidences of diabetes [ 70 , 71 , 72 ], hypertension [ 73 ], and kidney disorders [ 74 , 75 ], among others, have been reported in individuals post-COVID-19 compared to non-COVID matched controls. Worsening of disease progression of existing clinical disorders has been reported in patients with hypertension [ 76 , 77 ], kidney disease [ 78 ], multiple sclerosis [ 79 , 80 , 81 , 82 , 83 , 84 ], dementia [ 85 , 86 , 87 ], and other neurological conditions [ 86 , 87 , 88 , 89 , 90 , 91 ] post-COVID-19 compared to non-COVID matched controls. We expect that there will be accelerated aging of multiorgan systems in some individuals, especially those with experience of severe acute COVID-19 and/or with major pre-existing comorbidities.…”

Section: Resultsmentioning

confidence: 99%

A Comprehensive Review of the Global Epidemiology, Clinical Management, Socio-Economic Impacts, and National Responses to Long COVID with Future Research Directions

Song,

Cui

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Background: Long COVID, characterized by a persistent symptom spectrum following SARS-CoV-2 infection, poses significant health, social, and economic challenges. This review aims to consolidate knowledge on its epidemiology, clinical features, and underlying mechanisms to guide global responses; Methods: We conducted a literature review, analyzing peer-reviewed articles and reports to gather comprehensive data on long COVID’s epidemiology, symptomatology, and management approaches; Results: Our analysis revealed a wide array of long COVID symptoms and risk factors, with notable demographic variability. The current understanding of its pathophysiology suggests a multifactorial origin yet remains partially understood. Emerging diagnostic criteria and potential therapeutic strategies were identified, highlighting advancements in long COVID management; Conclusions: This review highlights the multifaceted nature of long COVID, revealing a broad spectrum of symptoms, diverse risk factors, and the complex interplay of physiological mechanisms underpinning the condition. Long COVID symptoms and disorders will continue to weigh on healthcare systems in years to come. Addressing long COVID requires a holistic management strategy that integrates clinical care, social support, and policy initiatives. The findings underscore the need for increased international cooperation in research and health planning to address the complex challenges of long COVID. There is a call for continued refinement of diagnostic and treatment modalities, emphasizing a multidisciplinary approach to manage the ongoing and evolving impacts of the condition.

show abstract

Section: Resultsmentioning

confidence: 99%

A Comprehensive Review of the Global Epidemiology, Clinical Management, Socio-Economic Impacts, and National Responses to Long COVID with Future Research Directions

Song,

Cui

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Higher incidences of diabetes [68][69][70], hypertension [71], kidney disorders [72,73] among others have been reported in individuals post COVID-19 compared to non-COVID matched controls. Worsening of disease progression of existing clinical disorders have been reported in patients with hypertension [74,75], kidney disease [76], multiple sclerosis [77][78][79][80][81][82], dementia [83][84][85] and other neurological conditions [84][85][86][87][88][89] post COVID-19 compared to non-COVID matched controls. We expect that there will be accelerated aging of multiorgan systems in some individuals, especially those experienced severe acute COVID-19 and/or with major pre-existing comorbidities.…”

Section: New Clinical Disorders and Accelerated Disease Progressionmentioning

confidence: 99%

“…Advancing the development of monitoring methods for long COVID. Fagherazzi (2022) innovatively used various devices and vocal recordings of breathing to identify COVID-related symptoms, allowing for long-term monitoring of long COVID patients and predicting the evolution of their symptoms [80]. Kovarik (2023) utilized mass spectrometry-based post-genomic analysis techniques to identify symptoms associated with long COVID [103].…”

Section: Conducting Investigation To Develop Effective Treatment Stra...mentioning

confidence: 99%

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

Song,

Cui

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Long COVID, characterized by a persistent symptom spectrum following SARS-CoV-2 infection, poses significant health, social, and economic challenges. This review aims to consolidate knowledge on its epidemiology, clinical features, and underlying mechanisms to guide global responses; Methods: We conducted a systematic literature review, analyzing peer-reviewed articles and reports to gather comprehensive data on long COVID’s epidemiology, symptomatology, and management approaches; Results: Our analysis revealed a wide array of long COVID symptoms and risk factors, with notable demographic variability. The current understanding of its pathophysiology suggests a multifactorial origin yet remains partially understood. Emerging diagnostic criteria and potential therapeutic strategies were identified, highlighting advancements in long COVID management.; Conclusion: This review highlights the multifaceted nature of long COVID, revealing a broad spectrum of symptoms, diverse risk factors, and the complex interplay of physiological mechanisms underpinning the condition. Long COVID symptoms and disorders will continue to weigh on healthcare systems in years to come. Ad-dressing long COVID requires a holistic management strategy that integrates clinical care, social support, and policy initiatives. The findings underscore the need for increased international cooperation in research and health planning to address the complex challenges of long COVID. There is a call for continued refinement of diagnostic and treatment modalities, emphasizing a multidisciplinary approach to manage the ongoing and evolving impacts of the condition.

show abstract

“…Reports have indicated that relapses of NMOSD and MOGAD occur after COVID-19 infection, although the risk of relapse due to treatment interruption may be higher [ 17 , 18 ]. However, recent reports regarding a broader perspective have suggested that COVID-19 has no impact on disease activity or disease course in patients with MS [ 19 , 20 ]. Further long-term studies are needed to gain a comprehensive understanding of the clinical impact of COVID-19 infection on neuroimmunological disorders.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience

Ju,

Seok,

Chung

et al. 2024

Diagnostics

View full text Add to dashboard Cite

This study evaluates the antibody responses to SARS-CoV-2 vaccines in patients with neuroimmunological disorders (pwNID) who are receiving immunomodulating treatments, compared to healthy individuals. It included 25 pwNID with conditions such as optic neuritis, neuromyelitis optica spectrum disorder, multiple sclerosis, myasthenia gravis, and polymyositis, as well as 56 healthy controls. All participants had completed their full SARS-CoV-2 vaccination schedule, and their blood samples were collected within six months of their last dose. The concentration of anti-SARS-CoV-2 IgG antibodies was measured using an enzyme-linked immunosorbent assay. The results showed that pwNID had significantly lower antibody titers (58.4 ± 49.2 RU/mL) compared to healthy individuals (81.7 ± 47.3 RU/mL). This disparity persisted even after adjusting for age and the interval between the final vaccination and sample collection. A notable correlation was found between the use of immunomodulating treatments and reduced antibody levels, whereas mRNA vaccines were linked to higher antibody concentrations. The conclusion of this study is that immunomodulating treatments may reduce the effectiveness of SARS-CoV-2 vaccines in pwNID. This insight is crucial for healthcare providers in designing vaccination strategies and managing treatment plans for pwNID on immunomodulating therapies, highlighting the need for personalized approaches in this subgroup.

show abstract

Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study

Cited by 7 publications

References 27 publications

A Comprehensive Review of the Global Epidemiology, Clinical Management, Socio-Economic Impacts, and National Responses to Long COVID with Future Research Directions

A Comprehensive Review of the Global Epidemiology, Clinical Management, Socio-Economic Impacts, and National Responses to Long COVID with Future Research Directions

A Comprehensive Global Review of Epidemiology, Clinical Management, Socio-Economic Impacts and National Responses of Long COVID with Future Research Directions

Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience

Contact Info

Product

Resources

About